Skip to main content

Advertisement

Fig. 8 | Journal of Hematology & Oncology

Fig. 8

From: Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors

Fig. 8

Combinatorial effect of BET and BCL-2 inhibitor ABT-199 on WT-MYC and THL. a–c WT-MYC (U2932), DHL (DOHH2), and THL (Val) were treated with JQ1 alone (5 μM), a sublethal dose of ABT-199 alone (500 nM), or a combination of both, and survival assay was performed by annexin/PI staining. d WT-MYC (U2932) and THL (Val) cells were treated with I-BET (2.5 μM), ABT-199 (500 nM), and a combination of both, and the effects on BCL-XL, BCL-2, BIM, and MCL-1 proteins were investigated by western blotting using specific antibodies. Bar represents mean ± SD for three replicates from three different experiments. *p < 0.05, **p < 0.01, ***p < 0.005

Back to article page